RV144 trial: the first HIV vaccine with partial efficacy
Ensayo RV144: primera vacuna contra el VIH con eficacia parcial
- Date
- 2003-2009 · confidence high
- Place
- Rayong and Chonburi, Thailand
- Credited to
- Thai Ministry of Public Health and the US Army (Rerks-Ngarm et al.)
- Field
- Life & health
What was discovered
A trial with over 16,000 volunteers, with the ALVAC-HIV vaccine followed by AIDSVAX B/E, which reduced the risk of HIV infection by about 31%. It was the first signal of efficacy for an HIV vaccine and a guide for later vaccine design.
The 31.2% result was published in 2009 and was modest and statistically weak depending on the analysis; the follow-up trials (HVTN 702, 2020) showed no efficacy, and there is still no approved vaccine.
What it led to
- analyses of immune correlates of protection against HIV
- later trials in South Africa (HVTN 702)
- studies of IgG antibodies and the V1V2 response